The new Duke Center for Computational and Digital Health Innovation brings together researchers from the School of Medicine, School of Nursing, Pratt School of Engineering, and Trinity to use the power of technology to tackle health care challenges.

Duke researchers found a higher risk of symptomatic brain inflammation in patients with brain metastases who received dual immune-checkpoint blockade therapies within four weeks of a form of targeted radiation therapy.

When Hurricane Helene hit Western North Carolina, it left more than flood damage—it fostered mold and fungal growth. Now, a Duke University team is studying how post-disaster fungi could affect health and recovery in a warming world.

Duke University has signed an exclusive license with GeneVentiv Therapeutics, a Raleigh-based gene therapy company, to commercialize a gene therapy developed in the lab of Dwight Koeberl, MD, PhD, professor of Pediatrics in the Duke University School of Medicine.

Duke University Health System (DUHS) has been awarded funding from the Patient-Centered Outcomes Research Institute (PCORI) to implement electronic monitoring of patients’ self-reported symptoms during cancer treatment — potentially transforming cancer care at Duke.

As cases of measles continue to spread in the U.S., a Duke Global Health Institute expert says public health officials need to find better ways to talk about the importance of vaccines.

Duke's acquisition of the 123-bed, acute-care facility in Mooresville, North Carolina, represents a significant expansion of clinical services outside the greater Triangle area. The hospital has been renamed Duke Health Lake Norman Hospital.

For the first time in more than two decades, Duke University School of Medicine hosted the annual Latino Medical Student Association (LMSA) Southeast Regional Conference.

A program managed by Duke medical students helps high school and elementary school students learn about careers in science, technology, and medicine.

A multi-faceted study from Duke University School of Medicine researchers shows for the first time that blocking an under-studied enzyme called PKN2 may be the key to stopping aggressive, treatment-resistant cancers.